Top Story

Dapagliflozin, potassium-sparing diuretics lower HbA1c in type 2 diabetes

Dapagliflozin, potassium-sparing diuretics lower HbA1c in type 2 diabetes
October 19, 2016

NEW ORLEANS — The use of dapagliflozin in combination with potassium-sparing diuretics significantly lowered HbA1c, body weight and systolic blood pressure in patients with type 2 diabetes, according to study results presented at the American Diabetes Association Scientific Sessions.

“The co-administration of dapagliflozin (Farxiga, AstraZeneca) and potassium-sparing agents – including spironolactone – did not produce an increase in potassium levels; and the rate of significant hyperkalemia was numerically lower with dapagliflozin versus placebo in patients treated with potassium-sparing agents at baseline,” Mikhail N. Kosiborod, MD, of Saint Luke’s Health System in Missouri, told Endocrine Today.

Meeting News Coverage

Visceral adipose tissue holds clues to cardiometabolic risk

October 14, 2016
BOSTON — Intra-abdominal visceral fat plays a causal role in the development of almost all components of metabolic syndrome, irrespective of a person’s BMI…
Meeting News Coverage

Bariatric surgery ‘powerful’ tool for understanding biology of obesity

October 11, 2016
BOSTON — A physiological regulation of energy balance drives most obesogenic behavior, and bariatric surgery is likely to best option to “rewire the…
Meeting News Coverage

Insulin therapy in 2017: More options, but greater costs may limit use

October 10, 2016
BOSTON — Several new insulin therapies are anticipated for patients with diabetes in 2017; however, for many, cost may put the latest options out of reach…
In the JournalsPerspective

Intracoronary abciximab may improve primary PCI in patients with diabetes, STEMI

August 17, 2016
Administration of an intracoronary bolus of abciximab improved outcomes of primary PCI compared with the IV bolus in patients with diabetes and…

In the JournalsPerspective

AHA: ‘Sit less, move more’

August 15, 2016
Sedentary behavior, even among those who are physically active, is associated with greater risk for CVD, diabetes, impaired insulin sensitivity and…

Meeting News Coverage

Metabolic syndrome provides minimal prognostic value for serious adverse events after ACS

August 6, 2016
Metabolic syndrome provides marginal prognostic value for the risk for major cardiovascular events in patients without diabetes who were recently

In the Journals

Researchers identify contrasting associations between major lipid subfractions and risk for CAD, diabetes

August 5, 2016
A recent study published in JAMA Cardiology found that increased LDL, HDL and triglyceride levels are associated with lower diabetes risk, while…

In the Journals

Liraglutide does not improve clinical stability after hospitalization for HFrEF

August 4, 2016
Use of the diabetes drug liraglutide among patients recently hospitalized with HF with reduced ejection fraction did not improve post-hospitalization…

In the Journals

Higher BMI associated with onset of diabetes, not increased risk of MI, death

August 4, 2016
Interventions to decrease obesity may be more useful in reducing diabetes risk compared with risk of death for cardiovascular disease, according to…

In the Journals

Tree nut consumption linked to lower inflammatory biomarkers

August 4, 2016
Higher intake of tree nuts is associated with lower levels of the inflammatory biomarkers C-reactive protein and interleukin 6, according to new…

Meeting News CoverageVideo

VIDEO: EMPA-REG, LEADER trial results produce ‘exciting time’ for diabetes care

July 29, 2016
NEW ORLEANS — The results of the EMPA-REG Outcome study and the LEADER trial have expanded physicians’ armamentariums to be able to…

In the Journals

Adults with congenital heart disease at elevated risk for type 2 diabetes

July 21, 2016
Patients older than 30 years with congenital heart disease, particularly cyanotic congenital heart disease, have increased risk for developing type 2…

In the Journals

Risk for CV outcomes, all-cause death varies by DPP-IV, TZD use

July 19, 2016
In patients with type 2 diabetes, risk for cardiovascular disease, heart failure and all-cause mortality varies by diabetes drug classes, alone and…

More Headlines »